Teijin Limited et al v. Alkem Laboratories Limited et al
| Teijin Pharma Limited, Teijin Limited and Takeda Pharmaceuticals U.S.A., Inc. |
| Ascend Laboratories, LLC and Alkem Laboratories Limited |
| 1:2019cv00768 |
| April 26, 2019 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on June 21, 2019. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 10 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Alkem Laboratories Limited for Ascend Laboratories, LLC filed by Ascend Laboratories, LLC. (Farnan, Brian) |
| Filing 9 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Alkem Laboratories Limited. (Farnan, Brian) |
Filing 8
Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 8/21/2019, at 11:30 AM in Chambers before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 6/20/2019. (nms)
|
| Filing 7 ANSWER to #1 Complaint, by Alkem Laboratories Limited, Ascend Laboratories, LLC.(Farnan, Brian) |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Summons Issued with Magistrate Consent Notice attached as to Alkem Laboratories Limited on 4/29/2019; Ascend Laboratories, LLC on 4/29/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (nmg) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Takeda Pharmaceutical Company Limited, Corporate Parent Takeda Pharmaceuticals International, AG for Takeda Pharmaceuticals U.S.A., Inc. filed by Takeda Pharmaceuticals U.S.A., Inc. (nmg) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Teijin Limited for Teijin Pharma Limited filed by Teijin Limited, Teijin Pharma Limited. (nmg) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,361,676 B2; 8,372,872 B2; 9,107,912 B2. (nmg) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 3/16/2019. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 9/15/2021. (nmg) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) |
| Filing 1 COMPLAINT for PATENT INFRINGEMENT filed against Alkem Laboratories Limited and Ascend Laboratories, LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2629336.) - filed by Teijin Pharma Limited, Teijin Limited, Takeda Pharmaceuticals U.S.A., Inc. (Attachments: #1 Exhibit A-I, #2 Civil Cover Sheet)(nmg) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
